Tuesday, 29 September 2026European Markets

SEQUANA MEDICAL Stock Impressive Jump On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with SEQUANA MEDICAL (SEQUA.BR) jumping 13.36% to €2.80 on Thursday, after two consecutive sessions in a row of gains. BEL 20 dropped 1.86% to €3,398.58, after two consecutive sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

SEQUANA MEDICAL's last close was €2.47, 66.07% under its 52-week high of €7.28.

About SEQUANA MEDICAL

Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.36.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -690.43%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 17.3%, now sitting on 842.41k for the twelve trailing months.

Volume

Today's last reported volume for SEQUANA MEDICAL is 19238 which is 136.54% above its average volume of 8133.

More news about SEQUANA MEDICAL (SEQUA.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com